Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antisense Therapy

Antisense Therapy The technique of gene silencing using antisense oligonucleotides is of high interest to investigators involved in drug development. In theory, this technology provides a means of specifically targeting the expression of a single gene product. The ever-expanding field of antisense technology now covers a wide range of substances including oligonucleotides, peptide nucleic acids as well as small interfering ribonucleic acids or RNA interference. Antisense technology has developed over the past decade to the stage where there are now several clinical trials evaluating the safety as well as efficacy of these agents in clinical oncology. With rapid developments in synthesis of the oligonucleotides, modifications that make the oligonucleotides more stable, and identification of more tumor-specific targets, it is likely that antisense oligonucleotides will become useful in cancer therapy. These drugs appear to be well tolerated and may be combined with conventional chemotherapeutic agents for better antitumor effects. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/antisense-therapy-iYnG5c4sAx
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302040-00003
Publisher site
See Article on Publisher Site

Abstract

The technique of gene silencing using antisense oligonucleotides is of high interest to investigators involved in drug development. In theory, this technology provides a means of specifically targeting the expression of a single gene product. The ever-expanding field of antisense technology now covers a wide range of substances including oligonucleotides, peptide nucleic acids as well as small interfering ribonucleic acids or RNA interference. Antisense technology has developed over the past decade to the stage where there are now several clinical trials evaluating the safety as well as efficacy of these agents in clinical oncology. With rapid developments in synthesis of the oligonucleotides, modifications that make the oligonucleotides more stable, and identification of more tumor-specific targets, it is likely that antisense oligonucleotides will become useful in cancer therapy. These drugs appear to be well tolerated and may be combined with conventional chemotherapeutic agents for better antitumor effects.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References